Amgen faces patent infringement claims on big-selling osteoporosis drug Evenity
May 3, 2023
Source: drugdu
78
In developing its osteoporosis drug Evenity more than a decade ago, it is alleged in court documents that Amgen discussed forming a potential partnership with a small company from Kansas.
Those discussions never amounted to a deal. Now, 11 years later, the Kansas company is suing Amgen for patent infringement.
The suit, filed in U.S. District Court in Massachusetts, claims Amgen's Evenity infringes on three of patents owned by OssiFi-Mab, including one that was granted last month. The first patent was awarded in 2012, the same year that Amgen and the Kansas company talked of a potential collaboration, according to the suit.
The patents refer to the “discovery of methods of increasing bone density via administration of a sclerostin antagonist together with an antiresorptive,” the complaint says. Evenity works in part by decreasing bone resorption by inhibiting the action of sclerostin, which helps regulate bone metabolism.
Amgen declined to comment on the suit.
Reference:https://news.bloomberglaw.com/ip-law/amgen-sued-for-patent-royalties-on-evenity-osteoporosis-drug
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells May 17, 2024
- New DNA Origami Technique to Advance Disease Diagnosis May 17, 2024
- Blackstone Unveils Immunology Startup With $300M and a Phase 2-Ready Drug From Merck May 17, 2024
- FDA Approves Roche’s HPV Self-Collection Solution, Allowing Patients to Gather Their Own Samples in a Healthcare Setting May 17, 2024
- US study reveals interferon combinations cause lupus symptoms and affect treatment May 17, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
